AARD (AARD) reported G&A of $5.9M in Q1 2026.

How has AARD's G&A changed year-over-year?

AARD's G&A increased by 117.2% year-over-year, from $2.72M to $5.9M.

Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.

AARD AARD G&A

G&A at other companies

Relmada Therapeutics, Inc.RLMD

$11.37M+81.5%

Viking TherapeuticsVKTX

$13.98M-0.7%

ArvinasARVN

$19.1M-28.2%

Protagonist TherapeuticsPTGX

$13.28M+13.1%

Arcus BiosciencesRCUS

$29M+3.6%

Other financials

Income statement

See full

Revenue-—

Operating income-$22.5M-115%

Net income-$21.6M-132%

EPS (diluted)-$0.99-39.4%

Balance sheet

See full

Cash & equivalents$62.4M+136%

Total debt$336.0K-53.7%

Total equity$87.0M-42.3%

Total assets$98.6M-37.2%

Cash flow

See full

Operating cash flow-$18.9M-65.7%

CapEx--100%

Free cash flow-$16.8M-117%

Valuation

See full

Market cap$124.35M-58.6%

Enterprise value$62.25M-77.4%

Returns & leverage

See full

Return on equity-58.8%—

Debt / equity0×0.0×

Current ratio8.1×-17.8×

Where this comes from

Reported directly by AARD in its filing.

Tagged under the XBRL concept us-gaap:GeneralAndAdministrativeExpense.

The official record: AARD’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about AARD's g&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is AARD's G&A?: AARD (AARD) reported G&A of $5.9M in Q1 2026.
How has AARD's G&A changed year-over-year?: AARD's G&A increased by 117.2% year-over-year, from $2.72M to $5.9M.
What does G&A mean?: Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.